Complete all fields to ensure full traceability of the affected material. All fields in this section are mandatory for regulatory compliance.
Product Batch/Lot Number
Product Code/Catalog Number
Product Type Classification
Allogeneic Cell Therapy
Autologous Cell Therapy
Viral Vector Gene Therapy
Ex vivo Gene-Modified Cells
Primary Cell Line
Immortalized Cell Line
Other Cellular Product
Product Description & Intended Use
Cryo-Vessel Unique Identifier
Cryo-Vessel Type
Liquid Nitrogen Dewar (Vapor Phase)
Liquid Nitrogen Dewar (Liquid Phase)
Ultra-Low Freezer (-150°C)
Dry Vapor Shipper
Controlled-Rate Freezing Container
Other
Cryo-Vessel Capacity (Number of Vials/Bags)
Number of Affected Units in This Deviation
Is this a qualified and validated shipping container?
Date of Last Qualification/Re-qualification
Explain why non-qualified container was used and provide risk assessment reference
Temperature Logger/Sensor ID
Shipment Departure Date & Time (Local)
Shipment Received Date & Time (Local)
Origin Site/Manufacturing Facility
Destination Site/Receiving Facility
Third-Party Logistics Provider (3PL) / Carrier
Was the container sealed with tamper-evident device?
Describe security measures and integrity verification upon receipt
Document the temperature deviation with precise temporal and thermal data. Attach continuous monitoring graphs and photographs of data logger displays.
Date & Time of Deviation Discovery
Name of Person Discovering Deviation
Was temperature monitoring continuous throughout transit?
Data Logging Interval (Minutes)
Explain monitoring gaps and provide manual temperature check records
Specified Storage Temperature (°C)
Maximum Temperature Recorded During Deviation (°C)
Minimum Temperature Recorded During Deviation (°C)
Calculated Duration Above Critical Threshold (Minutes)
Did temperature exceed the product-specific critical threshold?
Provide product-specific stability data justification for this threshold
Was liquid nitrogen (LN2) level adequate at departure?
Document LN2 fill level at departure and identify responsible personnel
Was LN2 level checked and adequate upon arrival?
Document LN2 level at arrival and immediate corrective actions taken
Select all potential root causes for the temperature deviation
Equipment failure (dewar/vessel)
Temperature monitoring device malfunction
Insufficient LN2 fill prior to shipment
Extended transit time beyond validated duration
Ambient temperature extremes during transport
Improper handling/orientation
Customs/Regulatory delay
Other
Detailed narrative description of deviation event timeline
Upload continuous temperature monitoring data file (CSV, PDF report, or proprietary format)
Upload photographs of data logger display showing deviation event
Manual Temperature Log (if continuous monitoring was unavailable)
Timestamp | Temperature Reading (°C) | Personnel Initials | Measurement Method | ||
|---|---|---|---|---|---|
A | B | C | D | ||
1 | |||||
2 | |||||
3 | |||||
4 | |||||
5 | |||||
6 | |||||
7 | |||||
8 | |||||
9 | |||||
10 |
Rate the severity of this temperature deviation (1 = Minor, 5 = Critical Product Loss)
All testing must be initiated within 24 hours of deviation discovery unless scientifically justified. Results must be reviewed by Qualified Person before final disposition.
Were viability and contamination tests initiated within the required timeframe?
Explain delay and provide scientific justification for extended hold time
Date & Time Testing Initiated
Viability Assay Results (test minimum 3 vials/bags)
Vial/Bag ID | Assay Type | Pre-Deviation Viability (%) | Post-Deviation Viability (%) | Acceptance Criterion (%) | Within Specification? | ||
|---|---|---|---|---|---|---|---|
A | B | C | D | E | F | ||
1 | |||||||
2 | |||||||
3 | |||||||
4 | |||||||
5 | |||||||
6 | |||||||
7 | |||||||
8 | |||||||
9 | |||||||
10 |
Did any viability results fall below acceptance criteria?
Describe observed cellular morphology changes and functional concerns
Select all contamination tests performed
Sterility (Bacteriostasis/Fungistasis)
Mycoplasma PCR
Endotoxin (LAL)
Adventitious Agent (14-day in vitro)
Viral Safety (PCR/NGS)
Other
Contamination Test Results Summary
Test Name | Test Completion Date | Result (Pass/Fail/Inconclusive) | Specification Reference | Attach Certificate of Analysis | ||
|---|---|---|---|---|---|---|
A | B | C | D | E | ||
1 | ||||||
2 | ||||||
3 | ||||||
4 | ||||||
5 | ||||||
6 | ||||||
7 | ||||||
8 | ||||||
9 | ||||||
10 |
Did any contamination tests fail or show positive results?
Detail the nature of contamination and potential source correlation with temperature deviation
Is this a gene therapy product requiring genetic stability assessment?
Select genetic stability tests performed
Vector Copy Number (qPCR)
Transgene Expression (Flow Cytometry)
Integration Site Analysis (NGS)
Karyotype/Genomic Integrity
Next-Generation Sequencing (Full Genome)
Other
Rate the impact of temperature deviation on critical quality attributes
No Impact | Minimal Impact | Moderate Impact | Severe Impact | Critical Failure | |
|---|---|---|---|---|---|
Cellular Viability | |||||
Phenotypic Identity | |||||
Potency/Function | |||||
Purity (cellular) | |||||
Genetic Stability (if applicable) | |||||
Sterility Assurance |
Upload complete testing laboratory reports and raw data files
Based on deviation severity and testing results, determine appropriate material disposition. All decisions require formal risk assessment and multi-departmental authorization.
Date & Time of Quarantine Initiation
Quarantine Physical Location & Storage Conditions
Proposed Final Disposition
Release to Clinical/Manufacturing Use
Quarantine Pending Additional Testing
Rework/Reprocessing
Destroy by Incineration
Destroy by Autoclave
Return to Supplier/Sponsor
Scientific & Risk-Based Justification for Proposed Disposition
Has a formal risk assessment been completed and documented?
Risk Assessment Document Number
STOP: Complete risk assessment before proceeding. This form cannot be approved without documented risk analysis.
Estimated Financial Value of Affected Material
Estimated Cost of Rework (if applicable)
Will this disposition impact any active clinical trial or patient treatment?
Describe patient impact mitigation plan and notification strategy
Multi-Department Authorization Matrix
Department/Function | Authorized Person Name | Title/Role | Authorization Timestamp | Approve Disposition? | Comments/Conditions | ||
|---|---|---|---|---|---|---|---|
A | B | C | D | E | F | ||
1 | Quality Assurance | ||||||
2 | Manufacturing/Processing | ||||||
3 | Supply Chain & Logistics | ||||||
4 | Regulatory Affairs | ||||||
5 | Medical/Clinical Affairs | ||||||
6 | |||||||
7 | |||||||
8 | |||||||
9 | |||||||
10 |
If Rework is selected: Has a validated reprocessing protocol been approved?
Reprocessing Protocol Number & Version
Describe reprocessing method and validation strategy
If Destruction is selected: Has environmental disposal compliance been verified?
Waste Disposal Manifest Number
STOP: Contact Environmental Health & Safety before proceeding with destruction.
Final regulatory determination and executive quality approval. Ensure all notifications and escalations are completed before final sign-off.
Does this deviation require notification to regulatory authorities?
Select all applicable regulatory regions requiring notification
FDA (United States)
EMA (European Union)
PMDA (Japan)
NMPA (China)
Health Canada
TGA (Australia)
Other National Authority
Notified Body/Competent Authority
Have all required regulatory notifications been submitted within mandated timeframes?
Provide justification for delayed notification and interim risk mitigation measures
Date & Time of Regulatory Notification Submission (if applicable)
Regulatory Notification Reference Number
Has this incident been escalated to the Pharmacovigilance department?
Pharmacovigilance Case Number
I confirm that all information provided in Sections 1-4 is complete and accurate to the best of my knowledge
I confirm that all mandatory testing has been completed and reviewed by a Qualified Person
I confirm that risk assessment adequately evaluates patient safety and product quality impact
I confirm that all regulatory obligations have been identified and fulfilled or are in progress with acceptable justification
Quality Director/Head of Quality Assurance Digital Signature
Quality Director Printed Name
Final Approval Date & Time
Does this deviation necessitate a CAPA (Corrective and Preventive Action) investigation?
CAPA Investigation Number
Upload all supporting documentation: temperature graphs, test reports, risk assessments, regulatory correspondence, and photographs
To configure an element, select it on the form.